Sarcomas are rare cancers arising in bone or soft tissue — muscle, fat, blood vessels, nerves. About 16,000 people are diagnosed in the U.S. each year. Treatment usually involves surgery, often with radiation or chemotherapy. Outcomes vary widely by subtype and stage, with some sarcomas responding well to standard treatment and others proving resistant.
What's actually going on in research
Trials are testing targeted therapies matched to specific genetic mutations, immunotherapy combinations adapted for sarcomas, antibody-drug conjugates that deliver chemotherapy directly to tumor cells, and CAR T-cell therapy for synovial sarcoma. Researchers are also studying whether imaging techniques can predict response early, sparing people from ineffective treatment.
Targeted therapies by mutation
Some sarcomas carry mutations in genes like NTRK, ALK, or BRAF. Drugs targeting these specific changes have shown responses in heavily treated patients, with trials now testing them earlier in treatment.
Immunotherapy combinations
Checkpoint inhibitors alone rarely work in sarcoma, but combinations with radiation, chemotherapy, or drugs that expose hidden tumor antigens are producing more responses. Several trials are testing these pairings in different sarcoma subtypes.
CAR T-cell therapy
Engineered T-cells targeting a protein called NY-ESO-1 have produced remissions in synovial sarcoma, a subtype common in young adults. Trials are testing refined versions and expanding to other sarcoma types.
What to know before you search
Eligibility typically depends on sarcoma subtype, disease stage, prior treatments, specific genetic mutations, and performance status.
What types of trials are currently open
- Targeted therapy trials — Testing drugs matched to specific genetic changes in your tumor, such as NTRK fusions or MDM2 amplification.
- Immunotherapy trials — Testing checkpoint inhibitors, CAR T-cells, or combinations designed to help the immune system recognize sarcoma cells.
- Chemotherapy trials — Testing new chemotherapy drugs or combinations, sometimes with targeted agents, to shrink tumors before surgery or treat advanced disease.
- Surgery and radiation trials — Studies of surgical techniques, radiation timing, or intraoperative therapies to improve local control and preserve function.
- Biomarker studies — Research tracking genetic changes in tumors over time or testing imaging methods to predict which treatments will work.
Recently added Sarcoma trials
Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
The primary objective of this trial is to evaluate the safety and tolerability of the tumor neoantigen vaccine (SarcVac) in combination with a PD-1 antibody, with or without tumor-specific lymphocytes, in patients with advanced bone and soft tissue sarcoma who have failed first-line treatment. The secondary objectives are to assess the preliminary efficacy of SarcVac combined with a PD-1 antibody, with or without tumor-specific lymphocytes, in these patients and to evaluate whether the vaccine's efficacy demonstrates dose dependency.
Study of the Impact of Digital Health Interventions on Symptom & Side-Effect Management in Metastatic Sarcoma Patients
The objective of this prospective study is to capture the quality of life of patients with locally advanced or metastatic sarcoma, and investigate the effectiveness of support provided through a personalized web-based platform.
Find Sarcoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.